Key Takeaway
Wegovy (semaglutide 2.4mg) produces an average weight loss of 14.9% of body weight[1] over 68 weeks, based on the STEP-1 trial. For a 250-pound person, that translates to about 37 pounds. About one-third of patients lose 20% or more.
Weight loss isn't instant: the first noticeable results come at 4 to 6 weeks, with the steepest losses during months 3 to 9.
How Much Weight Does Wegovy Help You Lose?
The STEP-1 clinical trial provides the most reliable data on Wegovy weight loss. Over 68 weeks, patients taking semaglutide 2.4mg lost an average of 14.9% of their starting body weight, compared to 2.4% for placebo. That 12.5 percentage point difference represents the true drug effect beyond what diet and exercise alone accomplish.
Results varied significantly between individuals. About 86% of patients lost at least 5% of body weight, which is the threshold considered clinically meaningful. Roughly 69% lost 10% or more.
And about 32% achieved the "super-responder" threshold of 20% or greater weight loss.
On the other end, about 14% of patients did not reach the 5% threshold and are considered non-responders. Individual response depends on genetics, adherence, lifestyle factors, and metabolic starting point. If you haven't lost at least 5% after 4 to 5 months at the full dose, your provider should discuss whether Wegovy is the right fit.
What Does the Month-by-Month Weight Loss Timeline Look Like?
Weight loss on Wegovy follows a predictable pattern tied to the dose titration schedule. The first 4 months involve gradual dose increases, during which weight loss is modest. The steepest losses occur once you reach the maintenance dose of 2.4mg.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
Here is a realistic month-by-month breakdown based on clinical data and our clinical experience at FormBlends. For a complete cost breakdown, see our cheapest GLP-1 without insurance.
| Month | Dose | Expected Weight Loss | Cumulative Loss |
|---|---|---|---|
| Month 1 | 0.25mg | 2 to 4 lbs | 2 to 4 lbs |
| Month 2 | 0.5mg | 3 to 5 lbs | 5 to 9 lbs |
| Month 3 | 1.0mg | 4 to 6 lbs | 9 to 15 lbs |
| Month 4 | 1.7mg | 4 to 7 lbs | 13 to 22 lbs |
| Month 5 | 2.4mg (full dose) | 4 to 6 lbs | 17 to 28 lbs |
| Months 6 to 9 | 2.4mg | 3 to 5 lbs/mo | 26 to 43 lbs |
| Months 10 to 16 | 2.4mg | 1 to 3 lbs/mo | 33 to 50 lbs |
These numbers represent typical ranges, not guarantees. Some patients lose faster early on and plateau sooner. Others have a slower start but continue losing steadily for a longer period.
The important thing is the overall trajectory, not any single week or month.
What Is the Wegovy Dosing Schedule?
Wegovy uses a 5-step dose escalation to minimize GI side effects. You inject once weekly, on the same day each week, and increase the dose every 4 weeks until reaching the maintenance dose. The full schedule takes about 16 to 20 weeks before reaching the target dose of 2.4mg.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →- Weeks 1 to 4: 0.25mg weekly
- Weeks 5 to 8: 0.5mg weekly
- Weeks 9 to 12: 1.0mg weekly
- Weeks 13 to 16: 1.7mg weekly
- Week 17 onward: 2.4mg weekly (maintenance dose)
Some patients experience significant GI side effects at certain dose steps. In those cases, providers may extend the time at a given dose before increasing. This is a standard and appropriate modification.
Rushing the titration to get to the full dose faster usually backfires with more severe nausea and vomiting.
What Side Effects Should You Expect?
GI side effects are the most common experience on Wegovy, especially during dose increases. Nausea affects 20 to 44% of patients. Diarrhea affects 15 to 30%.
Vomiting occurs in 5 to 24%. These typically peak in the first 1 to 2 weeks after each dose increase and fade as your body adjusts.
Constipation is common (10 to 24%) and can persist throughout treatment. Headache, fatigue, and dizziness affect a smaller percentage of patients. Injection site reactions are generally mild, just slight redness or tenderness that resolves within a day.
Serious side effects are rare but include pancreatitis, gallbladder problems (particularly gallstones), and acute kidney injury (usually from dehydration due to GI symptoms). Wegovy carries a boxed warning about thyroid C-cell tumors based on animal studies, though this hasn't been confirmed in humans.
How Much Does Wegovy Cost and What Are Cheaper Alternatives?
Brand-name Wegovy retails at about $1,350 per month. With commercial insurance and the Novo Nordisk savings card, some patients pay as little as $0 to $500 per month. Without insurance or savings programs, the cost puts Wegovy out of reach for most people paying out of pocket.
| Option | Monthly Cost | Notes |
|---|---|---|
| Wegovy (Brand, No Insurance) | ~$1,350 | Pre-filled pen, all doses same price |
| Wegovy (With Savings Card) | $0 to $500 | Commercial insurance required, eligibility varies |
| Compounded Semaglutide | $199 to $399 | Same active ingredient, vial format, from 503B pharmacy |
| Ozempic (Off-Label) | $900 to $1,100 | Max dose 2.0mg, approved for diabetes only |
Compounded semaglutide offers the same active molecule at a fraction of the price. FormBlends provides compounded semaglutide starting at $199/month through licensed 503B pharmacy partners, with physician oversight and ongoing clinical support included.
What Happens if You Stop Taking Wegovy?
Weight regain after discontinuation is well documented. The STEP-1 extension study found that patients who stopped semaglutide after 68 weeks regained about two-thirds of their lost weight within 52 weeks. Appetite returned, calorie intake increased, and the metabolic benefits of the drug reversed.
This isn't a failure of the medication. It reflects the biology of obesity: the hormonal and neurological changes that drove weight gain in the first place don't disappear because you lost weight. Wegovy works by correcting those signals, and when the drug is removed, the signals return.
For this reason, most obesity medicine specialists now recommend long-term or indefinite GLP-1 therapy for patients who have achieved meaningful weight loss. Some patients can maintain weight on a lower dose than their peak treatment dose, reducing both cost and side effects while preserving results.
How Can You Maximize Weight Loss on Wegovy?
Wegovy works best when combined with lifestyle modifications. Clinical trial participants all received diet and exercise counseling alongside the medication, and real-world outcomes tend to be best among patients who actively pursue both.
Protein intake matters. Aim for 0.7 to 1.0 grams of protein per pound of ideal body weight daily. Adequate protein preserves lean muscle mass during rapid weight loss, which protects your metabolic rate and improves body composition. GLP-1 medications suppress appetite, so making each calorie count toward protein is important.
Resistance training helps. Strength training 2 to 3 times per week protects against the muscle loss that accompanies any significant weight reduction. Studies show that GLP-1 weight loss includes some lean mass loss. Resistance exercise is the most effective countermeasure.
Does Wegovy Reduce Heart Disease Risk?
Yes. The SELECT trial, published in 2023, demonstrated that semaglutide 2.4mg reduced the risk of major adverse cardiovascular events by 20% in patients with obesity and established cardiovascular disease. This included a reduction in heart attacks, strokes, and cardiovascular death.
This benefit occurred regardless of diabetes status.
SELECT enrolled over 17,600 patients and followed them for a mean of 40 months. It was the first trial to show that a weight loss medication could directly reduce cardiovascular events. This finding increased Wegovy from a weight management tool to a cardiovascular risk reduction therapy.
For patients with existing heart disease or high cardiovascular risk, Wegovy offers a dual benefit that no other weight loss medication currently matches. This cardiovascular evidence is one of Wegovy's key advantages over newer competitors like Zepbound (tirzepatide), which hasn't yet completed cardiovascular outcomes testing.
Frequently Asked Questions
How much weight can you lose on Wegovy?
The average is 14.9% of body weight[1] over 68 weeks. For a 250-pound person, that's about 37 pounds. About one-third of patients lose 20% or more.
Results vary based on individual factors.
How fast does Wegovy work?
Appetite changes start within 1 to 2 weeks. Visible weight loss typically begins at 4 to 6 weeks. The fastest weight loss occurs during months 3 to 9 at the full 2.4mg dose.
How much does Wegovy cost?
Brand-name Wegovy costs about $1,350/month at retail. With insurance and manufacturer savings cards, it can drop to $0 to $500/month. Compounded semaglutide starts at $199/month.
What happens when you stop taking Wegovy?
The STEP-1 extension study showed patients regained about two-thirds of lost weight within one year of stopping. Long-term or indefinite treatment is generally recommended for sustained results.
Does Wegovy work for everyone?
About 86% of patients lose at least 5% of body weight, the threshold for clinical significance. Roughly 14% are non-responders. If you haven't lost 5% after 4 to 5 months at full dose, discuss alternatives with your provider.
What is the Wegovy dosing schedule?
Start at 0.25mg weekly, increase every 4 weeks through 0.5mg, 1.0mg, 1.7mg, to the maintenance dose of 2.4mg. Full dose is typically reached by month 5.
Can you take Wegovy with other medications?
Wegovy is compatible with most medications but slows gastric emptying, which may affect absorption of some oral drugs. Your provider should review all medications before starting. Never combine Wegovy with other GLP-1 drugs.
Does Wegovy reduce heart disease risk?
Yes. The SELECT trial showed semaglutide 2.4mg reduced major cardiovascular events by 20% in patients with obesity and established heart disease, regardless of diabetes status.
Medical References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →